126 Păunescu V.<strong>Jurnalul</strong> <strong>de</strong> <strong>Chirurgie</strong> (Iaşi), 2013, Vol. 9, Nr. 261. Johnson CD. U.K. gui<strong>de</strong>lines for themanagement of acute pancreatitis. Gut. 2005;54(Suppl.3): iii1 – iii9.62. Chauhan S, Forsmark CE. The difficulty inpredicting outcome in acute pancreatitis. Am JGastroenterol. 2010; 105(2): 443-445.63. Miles KA, Griffiths MR. Perfusion CT: aworthwhile enhancement? Br J Radiol. 2003;76(904): 220-231.64. Thoeni RF. The revised Atlanta classificationof acute pancreatitis: its importance for theradiologist and its effect on treatment.Radiology. 2012; 262(3): 751-764.
ARTICOLE DE SINTEZĂ 127<strong>Jurnalul</strong> <strong>de</strong> <strong>Chirurgie</strong> (Iaşi), 2013, Vol. 9, Nr. 2CHIMIOTERAPIA HIPERTERMICĂ INTRAPERITONEALĂ(CHIP) ASOCIATĂ CITOREDUCŢIEI TUMORALE ÎNTRATAMENTUL CARCINOMATOZEI PERITONEALE DEETIOLOGIE COLORECTALĂI. Huțanu 1,2 , I. Radu 1,2 , B. Filip 1,2 , Mihaela Buna 2 , Maria Gabriela Aniţei 1,2 ,M. Deraco 3 , V. Scripcariu 1,2 1) Universitatea <strong>de</strong> Medicină și Farmacie „Gr.T. Popa” Iași2) Clinica I <strong>Chirurgie</strong> Oncologică, Institutul Regional <strong>de</strong> Oncologie Iași3) Department of Surgery, Fondazione IRCCS, Istituto Nazionale Tumouri Milano, Milano, Italia;Peritoneal Surface Malignancy ProgramHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY WITH CYTOREDUCTIVESURGERY FOR THE TREATMENT OF PERITONEAL CARCINOMATOSIS FROMCOLORECTAL ORGIN (Abstract): Peritoneal carcinomatosis due to gastrointestinalmalignancies has been consi<strong>de</strong>red a poor prognosis entity. Few prospective studies have shown 6to 12 months suvirval period for peritoneal carcinomatosis of colorectal cancer (CR) treated withsystemic chemotherapy. New chemotherapeutic agents and monoclonal antibodies increasedsurvival to 16-22 months. Despite this new systemic treatment most patients will die due tocachexia, peritonitis and/or intestinal occlusion. Normothermic or hyperthermic intraperitonealchemotherapy, intraoperative or early postoperative became in the last three <strong>de</strong>ca<strong>de</strong>s the standardtreatment for several malignancies of peritoneum and it has proven effective in peritonealcarcinomatosis of colorectal and ovarian origin. The main drawbacks of this method is lack ofstudies to confirm the benefits. A long learning curve, high morbidity and mortality, lack ofstudies on quality of life and the high cost of this procedure appears to be the most importantdisadvantages of this method. Recent studies including carreful selected patients show a five yearsuvirval rate of 40%, median survirval period of 30 months, high morbidity (up to 60%) and amortality up to 8%. Phase III trials on patients with peritoneal carcinomatosis from colorectalcancer treated with HlPEC are still ongoing. We present and review the latest results from theliterature regarding the value of HIPEC in peritoneal carcinomatosis from colorectal origin.KEY WORDS: PERITONEAL CARCINOMATOSIS; COLORECTAL CANCER; HYPER-THERMIC INTRAPERITONEAL CHEMOTHERAPY; HIPEC; CYTOREDUCTIVESURGERYSHORT TITLE: Chimioterapia hipertermică intraperitoneală (CHIP) în CCRHyperthermic intraperitoneal chemotherapy (HIPEC) in CRCHOW TO CITE: Huțanu I, Radu I, Filip B, Buna M, Deraco M, Scripcariu V. [Hyperthermic intraperitonealchemotherapy with cytoreductive surgery for the treatment of peritoneal carcinomatosis from colorectal orgin] <strong>Jurnalul</strong> <strong>de</strong>chirurgie (Iaşi). 2013; 9(2): 127-136. DOI: 10.7438/1584-9341-9-2-3.INTRODUCERECancerul colorectal (CCR) are înEuropa o inci<strong>de</strong>nță anuală <strong>de</strong> 415.000 cazuri[1]. Mortalitatea anuală este estimată la peste200.000 <strong>de</strong>cese [1].Carcinomatoza peritoneală (CP) esteuna din căile <strong>de</strong> diseminare ale canceruluiCCR. Acest tip <strong>de</strong> evoluţie a CCR poateapare izolat fără metastaze sau a<strong>de</strong>nopatii,uneori fiind rezultatul rupturii tumorii înperitoneu (spontan sau în timpul actuluichirurgical). Nu are o simptomatologieparticulară, tabloul clinic suprapunându-sepe cel al tumorii primitive. Cu toatăReceived date: 28.01.2013Accepted date: 01.03.2013Adresa <strong>de</strong> corespon<strong>de</strong>nţă: Prof. Dr. Viorel ScripcariuClinica I <strong>Chirurgie</strong> Oncologică, Institutul Regional <strong>de</strong> Oncologie IaşiStr. General Henry Mathias Berthlot nr. 2-4, 700483, IaşiTel.: 0040 (0) 374 27 88 10Fax: 0040 (0) 374 27 88 02E-mail: vscripcariu@gmail.com
Change language